Page last updated: 2024-12-08

olamufloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID477670
CHEMBL ID2078925
SCHEMBL ID1851976
MeSH IDM0383834

Synonyms (27)

Synonym
167887-97-0
hsr-903
(s)-(-)-5-amino-7-(7-amino-5-azaspiro[2,4]hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid
5-amino-7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-quinoline-3-carboxylic acid
5-amino-7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid
(s)-5-amino-7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
A810914
olamufloxacin
CHEMBL2078925
olamufloxacin [inn]
ljg8kl1435 ,
unii-ljg8kl1435
(-)-5-amino-7-((s)-7-amino-5-azaspiro(2,4)hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxo-3-quinolinecarboxylic acid
3-quinolinecarboxylic acid, 5-amino-7-(7-amino-5-azaspiro(2,4)hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxo-, (s)-
(-)-5-amino-7-((s)-7-amino-5-azaspiro(2,4)hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxo-3-quinolinecarboxylic acid,
AKOS015907629
olamufloxacin [who-dd]
5-amino-7-[(7s)-7-amino-5-azaspiro[2.4]hept-5-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid
LEILBPMISZFZQK-GFCCVEGCSA-N
5-amino-7-((s)-7-amino-5-azaspiro[2.4]hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid
J-502473
SCHEMBL1851976
hsr903
gtpl10838
Q27283030
3-quinolinecarboxylic acid, 5-amino-7-[(7s)-7-amino-5-azaspiro[2.4]hept-5-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxo-
5-amino-7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Research Excerpts

Treatment

ExcerptReferenceRelevance
"When treated with olamufloxacin (5 mg/kg given orally twice a day) for 7 days, 11 of 12 L."( In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp.
Arakaki, N; Higa, F; Kawakami, K; Koide, M; Saito, A; Shinzato, T; Tateyama, M, 2003
)
0.92

Dosage Studied

ExcerptRelevanceReference
" The concentration of theophylline in serum and the urinary excretion rates of theophylline on day 5 of concomitant dosing with HSR-903 tended to increase compared to those on day 4, when theophylline was given alone; however, the urinary excretion rates of 1-methyluric acid and 3-methylxanthine on day 5 of concomitant dosing with HSR-903 tended to decrease in comparison to those on day 4, when theophylline was given alone."( Effect of HSR-903, a new fluoroquinolone, on the concentration of theophylline in serum.
Matsuoka, O; Matsushima, T; Miyashita, N; Nakajima, M; Niki, Y; Sekino, H; Tamada, S; Watanabe, S; Yoshida, K, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (61.11)18.2507
2000's7 (38.89)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]